NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
Clinical Trials
13 trialsNCT00068393 2023-07-07
Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01164228 2023-06-15
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00121251 2021-04-06
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00496587 2017-07-19
Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00401128 2017-04-20
Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer
The Cleveland Clinic
Phase 2 Completed
NCT00004095 2017-04-18
Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
Northwestern University
Phase 1 Completed
NCT00630409 2017-03-10
Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma
University of Pittsburgh
Phase 2 Completed
NCT00042965 2016-07-14
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00556049 2016-04-21
Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
Massachusetts General Hospital
Phase 2 Completed
NCT00058318 2012-11-02
S0312, Gemcitabine and Capecitabine in Treating Patients With Advanced Renal Cell (Kidney) Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00003928 2010-06-11
Gemcitabine Plus Cisplatin in Treating Patients With Metastatic Kidney Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00496301 2009-01-14
SOGUG-02-06
Spanish Oncology Genito-Urinary Group
Phase 2 Completed